Fred R. Hirsch, MD PhD
University of Colorado, Denver, CO
Dr. Hirsch’s program will leverage the resources of the recently established Squamous Lung Cancer Consortium (SLCC) of experienced clinical and biomarker investigators to validate preexisting gene expression signatures for prognosis of squamous cell carcinoma (SCC), with the goal to bring these signatures to a more broadly applicable clinical assay. These validated signatures can be used to identify patients with early stage SCC and provide for better selection of candidates for adjuvant therapy. The Consortium will also attempt to identify new targets for therapy for patients with SCC.
The project team includes investigators from the University of Colorado Denver, Mayo Clinic, the University of Michigan, The Brigham and Women’s Hospital, University of California Davis, Washington University St. Louis School of Medicine, Duke University Medical Center, and Princess Margaret Hospital, Toronto.
Specimens for these studies will be obtained from tissue banks at the participant institutions and from two multi-institutional protocols, ACOSOG Z4031 and CALGB 14202.
Statistical support will be provided by the Mayo Clinic.
Validate previously defined mRNA and miRNA expression signatures for prognosis in early stage SCC and to test the most robust of these signatures in two independent cooperative group clinical trial cohorts
Begin validation of genomic variants identified by NCI’s Cancer Genome Atlas Project, assess their prevalence and investigate whether they can supplement the prognostic power of the previously defined signatures
Establish a central SCC database including a virtual SCC tissue bank linked to molecular, pathological, and clinical information.